In brief
- Medsafe, New Zealand’s drug regulator, has authorized two psychiatrists to prescribe pharmaceutical-grade MDMA for post-traumatic stress disorder.
- The country becomes the second in the world, following Australia in 2023, to allow this therapy outside of a clinical trial.
- The full treatment costs up to 45,000 New Zealand dollars and is paid entirely by the patient.
New Zealand’s drug regulatory agency, Medsafe, has given the green light to two of the country’s psychiatrists to administer MDMA to patients with post-traumatic stress disorder (PTSD) outside the framework of a clinical trial. The authorization was made public on September 4, positioning New Zealand as the second country in the world, after Australia in 2023, to establish a legal and regulated pathway for this therapy.
Who can prescribe it
The authorized practitioners are Gary Wynn, a psychiatrist in Wellington, and Tom Paterson, in Auckland. Both had spent more than a year processing the permit with Medsafe, which requires demonstrating substantial experience in the field and submitting a detailed proposal on how the treatment would be administered with proper safeguards. For now, they are the only two professionals in the country authorized for this purpose, and they are not related to the two specialists already permitted to prescribe psilocybin since June 2025; these are separate lists with no overlap between professionals.
The protocol
The standard course consists of three sessions with doses between 120 and 160 milligrams of MDMA each, lasting four to six hours, accompanied by intensive psychotherapy before and after administration, with the support of music or other preparation tools. In total, this amounts to 54 hours of therapy. The drug is always taken in the office under clinical supervision—the patient does not take it home—and the treatment is part of a broader therapeutic plan available only to adults. The cost is borne by the patient: approximately 15,000 New Zealand dollars per round and up to 45,000 for the full three-session course, with no public funding available at this time.
What this means
Deputy Prime Minister David Seymour, who supported the measure, summarized it as follows: “PTSD ruins lives and is difficult to treat. MDMA can be highly effective in treating it through psychedelic-assisted therapy.” The decision is supported by previous trials with this substance: a 2021 study recorded significant improvements in 88% of participants, with 67% no longer meeting the diagnostic criteria for PTSD by the end of the study; another in 2023 raised that figure to 71.2%. It is important to keep the limitations in mind: for now, only two professionals can prescribe MDMA in the entire country, the price excludes those who cannot afford it, and the waiting list is expected to be long. It is a significant regulatory step, not a therapy available to just anyone with PTSD. For those who want to better understand this substance and its uses, both therapeutic and recreational, it is advisable to start with a general Psychedelics Guide and the principles of harm reduction and responsible use, which are useful in both clinical and non-clinical contexts.
Source
- RNZ. Party drug MDMA gets official approval as PTSD treatment. Radio New Zealand, September 4, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
